Á lódáil...
Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations
Background: Novel molecular therapies for metastatic breast cancer (MBC) are necessary to improve the dismal prognosis of this condition. Imatinib mesylate (Gleevec®) inhibits several protein tyrosine kinases, including platelet-derived growth factor receptor (PDGFR) and c-kit, which are preferentia...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , |
---|---|
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
Oxford University Press
2008
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2735063/ https://ncbi.nlm.nih.gov/pubmed/18515258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdn352 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|